Potential new Botox use? Antidepressant; Medco to pay $7.9M in kickbacks case; Novartis touts promising Afinitor data;

@FiercePharma: NIH steps in with $9M Vanderbilt grant after rough season for flu vaccines. More | Follow @FiercePharma

@EricPFierce: ICYMI: #FDA blesses Baxter #saline plant in Spain for shipments to U.S. of 0.9% sodium chloride. Article | Follow @EricPFierce

@CarlyHFierce: Novo, Baxter spar over hemophilia patent amid ITC probe. Story | Follow @CarlyHFierce

> Add "potential antidepressant" to Botox's list of uses; the Allergan injection, best known as a cosmetic, is also approved for a variety of medical indications, including migraine. Report

> Medco Health Solutions, an Express Scripts ($ESRX) subsidiary, said it would pay $7.9 million to settle allegations that it engaged in a kickback scheme with AstraZeneca ($AZN). Report

> Novartis ($NVS) said its cancer drug Afinitor helped delay cancer growth in patients with advanced neuroendocrine tumors. Report

> Pulmonary embolism patients aren't properly screened for the pulmonary hypertension that might follow, a Bayer study found. Report

> Hospitals urged Congress not to change a drug discount program that's designed to help facilities that serve a large proportion of needy patients. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: MD Anderson Cancer Center partners to start breast cancer pilot project using Apple Watch. Report | Follow @FierceMedDev

@VarunSaxena2: St. Jude says alternative imaging system is optimal during stenting procedures. Story | Follow @VarunSaxena2

@EmilyWFierce: San Francisco startup reels in $30M for disease outbreak prediction tech. More | Follow @EmilyWFierce

> Philips collaborates with Dutch hospital to develop diabetic foot disease Dx. More

> Issue that led to halt of St. Jude TAVR trial no cause for concern, EuroPCR experts say. News

Biotech News

@FierceBiotech: Regeneron's arthritis drug aces Phase III with the FDA in sight. News | Follow @FierceBiotech

@JohnCFierce: What's your list of top 5 public biotechs? (Potential, management, smart execution) I'd put $BLUE in that group. Any other suggestions? | Follow @JohnCFierce

> Pfizer vet Gutiérrez-Ramos takes the reins at Synlogic. Article

> Bluebird offers a promising peek at a potential cure for sickle cell. More

Vaccines News

> Canadian biotech Medicago building $200M vaccine plant. Item

> Genocea's genital herpes vaccine succeeds in Ph II. More

> Takeda, Daiichi Sankyo ink flu vaccine distribution pacts with Japan's Kaketsuken. Story

> Zydus Cadila preps for big splash into India's vaccines market. Article

> U.K.'s PsiOxus scores $39M for colorectal cancer vaccine combo trial. Report

CRO News

> Quintiles' founders bank $770M in secondary offering. Item

> InVentiv invests in compliance as regulations shift for real-world studies. Story

> Quotient Clinical soars in its first year after a PE buyout. Report

> WuXi posts another big quarter as it faces a big decision. Article

Pharma Manufacturing News

> Hospira recalls solution marked as heparin. Item

> Zydus Cadila said to be buying Claris' sterile injectables biz as landscape morphs. Story

> Apotex recalling generic Zyprexa because the antipsychotic may be too weak. News

> Fund grows to $200M for victims of meningitis outbreak tied to compounder. Article

> Medicago building $200M plant to manufacture vaccines from plants. Report

Pharma Asia News

> Sinocare said to bid $1B for Bayer diabetes devices, piping Panasonic. More

> China academy plans clinical trials on artemisinin derivative aimed at lupus. News

> Japan eyes higher target for generics despite missing earlier aims. Article

> Gilead's Sovaldi faces renewed advocacy CL pressure, this time for China and Russia. Story

> Glenmark gets India nod on shares sales to foreign investors, Temasek in. Report

And Finally... CareFirst BlueCross BlueShield said a cyberattack compromised the data of 1.1 million current and former members. Report

Suggested Articles

Belgian CDMO Ajinomoto Bio-Pharma Services has been on a run in recent of years expanding its operations around the world. That was the goal of an Ind

The company will commit $300 million over the next five years to hire more people of color and increase clinical trial diversity.

Moderna, after tapping almost $1 billion in federal funding, agreed to deliver 100 million doses of its vaccine candidate for up to $1.5 billion.